What is the diagnosis and treatment for oral candidiasis (Thrush)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Oral candidiasis is best treated with oral fluconazole (100 mg/day for 7–14 days), as it is as effective as—and, in some studies, superior to—topical therapy. This recommendation is based on the guidelines for treatment of candidiasis published in the Clinical Infectious Diseases journal 1. The treatment options for oral candidiasis include:

  • Clotrimazole troches (one 10-mg troche 5 times per day)
  • Nystatin (available as a suspension of 100,000 U/mL [dosage, 4–6 mL q.i.d.] or as flavored 200,000 U pastilles [dosage, 1 or 2 pastilles 4–5 times per day for 7–14 days])
  • Oral fluconazole (100 mg/day for 7–14 days)
  • Itraconazole solution (200 mg/day for 7–14 days)

It is essential to note that oral fluconazole and itraconazole solution are as efficacious as each other 1. However, ketoconazole and itraconazole capsules are less effective than fluconazole due to variable absorption 1.

For patients with recurrent episodes of oropharyngeal candidiasis, suppressive therapy is effective for preventing recurrent infections 1. Although it may increase the rate of development of isolates with an increased fluconazole MIC, the use of continuous suppression is recommended 1.

In clinical practice, it is crucial to address underlying factors that may contribute to the development of oral candidiasis, such as controlling blood sugar for diabetics, improving immune function, or discontinuing unnecessary antibiotics. Maintaining good oral hygiene, including regular brushing and cleaning of dentures if applicable, is also essential.

From the FDA Drug Label

Nystatin Oral Suspension, USP, is indicated for the treatment of candidiasis in the oral cavity. The recommended dosage of SPORANOX ® (itraconazole) Oral Solution for oropharyngeal candidiasis is 200 mg (20 mL) daily for 1 to 2 weeks.

Treatment Options for Oral Candidiasis:

  • Nystatin (PO) is indicated for the treatment of candidiasis in the oral cavity 2.
  • Itraconazole (PO) is recommended for the treatment of oropharyngeal candidiasis at a dosage of 200 mg (20 mL) daily for 1 to 2 weeks 3.

From the Research

Treatment Options for Oral Candidiasis

  • The most commonly used topical antifungal drugs for oral candidiasis are nystatin and miconazole, which are very effective but require a long treatment duration to eradicate the infection 4.
  • Other topical alternatives, such as amphotericin B or clotrimazole, may not be available in many countries, and their use may be limited by potential interactions with other drugs 4, 5.
  • Oral fluconazole is effective in treating oral candidiasis that does not respond to topical treatment, and it is considered a drug of choice for systemic treatment due to its good antifungal properties, high patient acceptance, and efficacy compared to other antifungal drugs 4, 6.
  • Other systemic treatment alternatives, such as itraconazole, voriconazole, or posaconazole, may be used in cases where Candida strains are resistant to fluconazole 4, 6, 7.
  • Novel approaches in antifungal therapy, including the use of probiotics, echinocandins (anidulafungin, caspofungin), and isavuconazole, are being explored as potential treatment options for oral candidiasis 4, 5.

Factors Influencing Treatment Outcomes

  • The incidence and treatment outcomes of oral candidiasis depend on the type of candidiasis, the virulence of the infection, and the presence of underlying risk factors, such as immunosuppression, diabetes, or broad-spectrum antibiotic use 5, 6, 8.
  • The treatment of oral candidiasis should take into account the potential for drug interactions and the development of antifungal resistance, particularly with the use of systemic antifungal agents 4, 5, 8.
  • Denture hygiene and the management of underlying risk factors are also important considerations in the prevention and treatment of oral candidiasis 8.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Therapeutic tools for oral candidiasis: Current and new antifungal drugs.

Medicina oral, patologia oral y cirugia bucal, 2019

Research

Fungal infections in dentistry: Clinical presentations, diagnosis, and treatment alternatives.

Oral surgery, oral medicine, oral pathology and oral radiology, 2020

Research

Current treatment of oral candidiasis: A literature review.

Journal of clinical and experimental dentistry, 2014

Research

Treatment of oral candidosis with itraconazole: a review.

Journal of the American Academy of Dermatology, 1990

Research

Candidiasis (oropharyngeal).

BMJ clinical evidence, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.